secondary hypertension

in review 7 min read Updated 2026-11-01
secondary hypertension

Think of it with resistant hypertension, hypokalaemia, an adrenal nodule, onset at a young age or sudden worsening, an abdominal bruit, AKI after starting RASi, or severe/malignant hypertension. Primary aldosteronism is the commonest treatable cause. Endocrine Society 2025 says screen everyone with hypertension (ARR). HTN Canada 2020 says screen only targeted groups. Phaeo: plasma free or urine fractionated metanephrines → α-blockade before any β-blocker.


who to work up

HTN Canada 2025 referral triggers: unexplained sudden worsening, hypokalaemia, adrenal nodule, abdominal bruit, AKI after starting antihypertensives, severe or malignant hypertension, hypertension at a young age, resistant hypertension.


primary aldosteronism — ES 2025 vs HTN Canada 2020

Endocrine Society 2025Hypertension Canada 2020
who to screenall adults with hypertension (2, low certainty; feasibility-dependent). Rescreen if hypertension worsens or becomes resistant, new hypokalaemia, or AF without structural heart diseasetargeted: spontaneous K⁺ <3.5 or diuretic-induced K⁺ <3.0; resistant to ≥3 drugs; incidental adrenal adenoma
screening testmorning, seated: aldosterone + renin (PRA or DRC) → ARR; measure K⁺ alongside (low K⁺ lowers aldosterone → false negative); don’t restrict sodiummorning, ambulatory ≥2 h then seated 5–15 min; correct K⁺, liberalise sodium
drug prepeither test on current drugs and interpret, or minimal withdrawal: stop MRA/ENaC inhibitors 4 wk (they raise renin → false-negative screen); β-blockers/central α₂-agonists 2 wk. Full withdrawal adds diuretics (4 wk) and ACEi/ARB/DHP CCB/SGLT2i (2 wk)stop MRA, K⁺-sparing and K⁺-wasting diuretics 4–6 wk. If non-diagnostic, stop β-blockers, central α₂-agonists, ACEi, ARB, DRI, DHP CCB for 2 wk
bridging drugshydralazine (+ verapamil SR), α₁-blockers, non-DHP CCB, moxonidineslow-release verapamil, diltiazem, hydralazine, prazosin, doxazosin, terazosin
positive screensuppressed renin (PRA ≤1 ng/mL/h or DRC ≤8.2 mU/L) + aldosterone ≥277 pmol/L (immunoassay) [≥208 LC-MS/MS] + ARR >70 pmol/L per mU/L (or >555 pmol/L per ng/mL/h); local cut-offs preferredARR (pmol/L per ng/mL/h) >555 (sensitive) or >750 (specific); per DRC mIU/L >60 / >91
confirmationaldosterone suppression test only if intermediate probability of lateralising PA and the patient wants surgery. Skip it if renin undetectable + aldosterone >554 pmol/L (immunoassay) with hypokalaemia or resistant hypertension, or if not a surgical candidate → start MRAalways: ≥1 of IV saline (2 L/4 h; PA if aldo >280 pmol/L, unlikely <140), oral salt load (24-h urine aldo >33 nmol/day), ARR >1400 with aldo >440 pmol/L, or captopril test
subtypingafter biochemical confirmation (incidentalomas common): CT + adrenal vein sampling before choosing surgery vs medical therapy. AVS can be skipped if age <35, marked PA, hypokalaemia and >1 cm unilateral adenomaCT/MRI, then AVS before unilateral adrenalectomy (an adrenal nodule may be non-functional)
also1-mg overnight dexamethasone test in every PA with adenoma (cortisol >50 nmol/L = autonomous cortisol secretion)genetic testing for GRA if FHx of PA or stroke ≤40 y, or onset ≤20 y with negative imaging
treatmentlateralising + surgical candidate → laparoscopic unilateral adrenalectomy. Otherwise lifelong MRA: spironolactone preferred (cost) over other MRAs, MRA over amiloride/triamterene. Titrate up to raise renin if BP uncontrolledunilateral → adrenalectomy; bilateral or non-surgical → MRA (spironolactone low–moderate dose)
  • ACC/AHA 2025 sits between the two: screen resistant hypertension (with or without hypokalaemia), any hypokalaemia (spontaneous or diuretic-induced), OSA, adrenal incidentaloma, family history of early-onset hypertension or stroke <40 y; consider in all stage 2 (≥140/90). Screen on current drugs, stopping only MRAs
  • ES 2025 repeat rules: negative screen with hypokalaemia → correct K⁺ and repeat; moderate–high pretest probability or suppressed renin with aldosterone 138–277 pmol/L → repeat on another day. On a β-blocker, aldosterone 277–416 pmol/L may be a false positive; above that, PA likely
  • ES 2025 renin cut-off: DRC ≤8.2 mU/L (the original Figure 1 printed mU/mL; corrected August 2025)
  • ES 2025: genetic screening for all first-degree relatives in familial hyperaldosteronism and for PA onset <20 y. Spironolactone default doesn’t apply if hyperkalaemia, advanced CKD or pregnancy; gynaecomastia → eplerenone (or amiloride)
  • MRA dosing (ES 2025): spironolactone 12.5–25 mg/day or eplerenone 25 mg daily–BID to start; 50 mg/day spironolactone if severe hypokalaemia. Check K⁺, Cr and renin within 2–3 months; adjust doses every 8–12 weeks
  • After treatment (surgery or MRA), eGFR often falls and Cr rises: removing the glomerular hyperfiltration unmasks underlying CKD → monitor renal function
  • CKD lowers renin and can raise aldosterone → more false-positive screens
interfering drugs

False positive (renin lowered): β-blockers, clonidine, methyldopa, NSAIDs, and oestrogen-containing OCP/HRT when renin is measured as DRC. False negative (renin raised): MRA, ENaC inhibitors, diuretics, ACEi/ARB, SGLT2i, and drospirenone (an MRA). Hypokalaemia → falsely low aldosterone. HTN Canada 2020: stop the OCP for 1 month, or measure PRA instead of DRC.

PA screening vs confirmation
  • HTN Canada 2020: ARR >1400 + aldosterone >440 pmol/L confirms PA (no suppression test needed)
  • ES 2025: suppressed renin is required — high ARR with unsuppressed renin is not PA

renovascular hypertension — HTN Canada 2020

atherosclerotic renal artery stenosis

  • Investigate if ≥2 of: onset or worsening at age >55 or <30; abdominal bruit; resistant to ≥3 drugs; Cr rise ≥30% on ACEi/ARB; other atherosclerotic disease; recurrent flash pulmonary oedema with BP surges
  • Screening tests: Doppler US, CTA, MRA (eGFR >30), captopril renal scan (eGFR >60). eGFR <30 → choose case by case with nephrology; avoid gadolinium MRA first
  • Medical therapy first: stenting adds nothing over optimal medical therapy (Grade B)
  • Angioplasty ± stent only for: hypertension resistant to maximal therapy, progressive renal function loss, or acute pulmonary oedema

fibromuscular dysplasia

  • Investigate if ≥1 of: unexplained kidney size asymmetry >1.5 cm, bruit without atherosclerosis, FMD elsewhere, family history of FMD
  • Screen with CTA or MRA (similar accuracy)
  • Confirmed → screen cervicocephalic arteries and for intracranial aneurysm; refer to a hypertension specialist
  • Angioplasty without stenting (stent only for periprocedural dissection)

phaeochromocytoma and paraganglioma

For full biochemical, imaging, genetic, and surgical detail, see phaeochromocytoma and paraganglioma.

who to test (HTN Canada 2020)

Paroxysmal/labile or severe (≥180/110) refractory hypertension; spells (headache, palpitations, sweating, pallor); hypertension triggered by β-blockers, MAOIs, micturition, surgery or anaesthesia; adrenal incidentaloma; hereditary syndromes (MEN2, NF1, VHL).

biochemistry

  • Plasma free metanephrines or urine fractionated metanephrines (ES 2014, strong rec). HTN Canada 2020 lists 24-h urine first with plasma “where available”. Never VMA
  • Plasma sample drawn supine, compared against supine reference ranges
  • ≥3× upper limit, or both normetanephrine and metanephrine raised → rarely false positive → image
  • Borderline → repeat supine. Still raised → clonidine suppression test
  • False positives: TCAs, SNRIs, MAOIs, sympathomimetics, D2 antagonists (metoclopramide, antipsychotics), acetaminophen (LC-ECD assays), critical illness
  • Image only after biochemical confirmation. ES 2014 prefers CT first. HTN Canada 2020 prefers MRI. MRI for skull base/neck, metastatic disease, or pregnancy
  • Offer genetic testing to all (shared decision). SDH testing for paraganglioma, SDHB if metastatic

pre-operative blockade

  • All functional tumours need pre-op blockade (ES 1); α-blocker first choice (2) (phenoxybenzamine, doxazosin or prazosin) for 7–14 days to normalise BP and HR (ES 2014). HTN Canada 2020 says 10–14 days
  • High-sodium diet + fluids → reverses volume contraction, prevents post-resection hypotension
  • β-blocker only after adequate α-blockade, for tachycardia. Avoid diuretics
  • Monitor BP, HR and glucose in the immediate post-op period (1)
  • Laparoscopic adrenalectomy for most; open if large (>6 cm) or invasive. Lifelong annual metanephrines
β-blocker before α-blockade

Unopposed α-stimulation → hypertensive crisis. Labetalol is no substitute: fixed α:β ≈ 1:5, so it can cause paradoxical hypertension. Don’t use it as initial therapy.

Prepared 2026-11-01. Not yet verified — check every number against the sources.

Key references

+3 more sources

Suggest a correction secondary hypertension